Review explores therapeutic strategies targeting eryptosis to enhance clinical outcomes in renal anemia and chronic kidney disease.
Key Points
Renal anemia is significantly influenced by accelerated eryptosis, leading to reduced red blood cell lifespan, and may impact treatment efficacy.
Approximately 50% of chronic kidney disease patients remain hypo-responsive to treatments like erythropoietin and iron supplements, indicating additional underlying causes.
Assessment focuses on molecular mechanisms of eryptosis, linking oxidative stress and uremic toxins to increased cellular death and its implications for anemia.
Innovative therapeutic strategies aim to target eryptosis, potentially shifting current approaches in managing renal anemia effectively.